25C-NBOMe



25C-NBOMe (NBOMe-2C-C, 2C-C-NBOMe, Cimbi-82) is a psychedelic drug and derivative of the psychedelic phenethylamine 2C-C. 25C-NBOMe appeared on online vendor sites in 2010 but was not reported in the literature until 2011. It acts as a potent agonist of the 5-HT2A receptor, and has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET). Multiple deaths have occurred from usage of 25C-NBOMe due to the ease of accidental overdose. The long-term toxic effects of the drug have not been researched.

History
25C-NBOMe is derived from the psychedelic phenethylamine 2C-C by substitution on the amine with a 2-methoxybenzyl group. 25C-NBOMe is a clumpy white powder with a notably bitter and metallic taste. 25C-NBOMe has been found on blotter mimics sold as LSD.

Dosage
25C-NBOMe is extremely potent and the effects of the drug increase greatly within a small window of dosage adjustment. Overdose may occur at as little as double an average dose. With inaccurate dosing of street blotter paper, when mistaken for LSD, or when taken as a powder or liquid, this has resulted in multiple accidental deaths.

One study has shown that 25C-NBOMe blotters have 'hotspots' of the drug and the dosage is not evenly applied over the surface of the paper, which could lead to overdose. Sublingually, the threshold for the onset of hallucinogenic effects reportedly is about 100–250 μg, with mild effects at 250–450, strong effects at 450–800, and very strong effects over 800 μg.

NBOMe-substituted compounds have a diminished absorption rate passing through mucus membranes, but generally remain inactive when taken orally. Buccal, sublingual or insufflated routes of administration are all viable options. Absorption rate buccally and sublingually can be increased when complexed with HPBCD complexing sugar, however the most efficient is nasal administration, which shortens the duration while increasing intensity, but has been attributed to several overdoses and deaths.

Desired

 * strong open- and closed-eye visuals, including trails, color shifts, brightening, etc.
 * mood lift
 * euphoria
 * mental and physical stimulation
 * increase in associative & creative thinking
 * increased awareness & appreciation of music
 * life-changing spiritual experiences
 * feelings of love and empathy
 * increased pattern recognition (psychology)
 * synesthesia and chromesthesia (intensified for those who experience these while sober)

Neutral

 * general change in consciousness
 * pupil dilation
 * unusual body sensations (paresthesia, flushing, chills, goose bumps)
 * change in perception of time, time dilation
 * increased heart rate
 * jaw clenching (bruxism)
 * yawning, especially when coming up
 * insomnia
 * looping, recursive, out-of-control thinking
 * dissociation

Undesired
(Includes negative side effects arising from overdose; likelihood of negative side effects increases with dose)
 * confusion and difficulty focusing
 * scrambled communication
 * tunnel vision
 * vasoconstriction leading to ischemia
 * nausea and vomiting (normally only during the onset for those affected)
 * paranoia, fear, and panic
 * irritation of the throat
 * irritation of mucous membranes
 * upper respiratory irritation and difficulty breathing/swallowing
 * unwanted and overwhelming feelings or life-changing spiritual experiences
 * syncope
 * shaking
 * seizure (higher in NBOMes compared to other psychedelics).
 * dystonia and clonus
 * death

Canada
As of October 31, 2016; 25C-NBOMe is a controlled substance (Schedule III) in Canada.

Israel
The NBOMe series of psychoactives became controlled in Israel in May, 2013.

New Zealand
25C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.

Russia
Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.

Sweden
Sveriges riksdag added 25C-NBOMe to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of Aug 1, 2013, published by Medical Products Agency in their regulation LVFS 2013:15 listed as 25C-NBOMe 2-(4-kloro-2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin.

United States
Several NBOMe series compounds will be temporarily scheduled in the United States for 2 years. The temporary scheduling applies to 25C-NBOMe, 25B-NBOMe, and 25I-NBOMe. In November 2015, the temporary scheduling was extended for another year.

China
As of October 2015 25C-NBOMe is a controlled substance in China.

Czech Republic
25C-NBOMe is banned in the Czech Republic.